4 August 2017 - Pharmacy benefit managers are still squeezing drugmakers for discounts.

Biopharma stocks have recovered from the drug-pricing terror that marked the beginning stages of the Trump administration. 

But as the flashier Washington price war, with congressional hearings and threats of legislation, stalls out, a quieter but more authentic battle continued this week, involving secret negotiations and closely scrutinized PDFs.

The country's biggest pharmacy benefit managers (PBMs), which negotiate drug discounts on behalf of insurers and employers, updated their growing lists of medicines they won't cover due to pricing or the availability of cheaper alternatives. Lobbying may work in D.C., but discounts work more often with PBMs.

Read Bloomberg article